Researcher in a protective suit and mask working at a laboratory safety cabinet

11 Jan 2019 Research

Myelofibrosis: Finding new ways to treat patients

Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.

Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.

Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.

The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

25 August 2020

Angela Smith-Morgan to step down from her role as Co CEO of Leukaemia UK

After eight successful years with us, Angela Smith-Morgan will be stepping down from her role as Co CEO of Leukaemia UK on 3rd September.

Leukaemia UK research paves the way for personalised lymphoma treatment

19 June 2023

Leukaemia UK research paves the way for personalised lymphoma treatment

Despite promising trials, standard treatment for diffuse large B-cell lymphoma (DLBCL) hasn’t changed in a decade. New treatment strategies for this type of blood cancer are urgently needed. Could the…

Leukaemia Care and Leukaemia UK announce financial support collaboration

19 August 2022

Leukaemia Care and Leukaemia UK announce financial support collaboration

Leukaemia Care and Leukaemia UK are pleased to announce a collaboration to provide financial support to people affected by leukaemia, through the financial hardship fund. Leukaemia Care have provided 364…

John Goldman Fellowships for 2023 now open

5 December 2022

John Goldman Fellowships for 2023 now open

Leukaemia UK is delighted to announce that we are funding more ground-breaking research in 2023, by continuing our investment in early career scientists and clinicians for our prestigious John Goldman…